Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Shares of Teva Pharmaceutical Industries Ltd. TEVA, +5.81% hiked up 5.0% toward a six-week high in afternoon trading Friday, putting them on track for a ninth-straight gain, after Bernstein analyst Aaron Gal turned bullish on the "long suffering" generic drug maker.

Teva stock jumps toward longest win streak in 2 years, after Bernstein analyst turns bullish

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stock was last seen up 4.7% at $8.55 this morning, following an upgrade from Bernstein.

This Pharma Stock's Luck May Be Changing, Says Analyst

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General of Rhode Island that settles the state's and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Rhode Island $21 million over 13-years and will provide its recently launched, lifesaving medicine generic Narcan® (naloxone hydrochloride n

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

The price of Teva Pharmaceutical stock has seen a fall of 17% in a month, while it is down 34% in the last year. The shares of generic drug makers have largely underperformed the broader markets over the last year or so, primarily due to concerns around the pricing environment and liabilities.

What's Next For Teva Pharmaceutical Stock After A 17% Fall In A Month?

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States. Teva's Lenalidomide capsules are a prescription medicine used in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone, (2) certain myelodysplastic

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

MONTRÉAL--(BUSINESS WIRE)--Teva Canada welcomes public formulary and program coverage making AJOVY® (fremanezumab) accessible to more migraine patients across Canada

Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in Adults

BRIDGEPORT, Conn., Feb. 21, 2022 /PRNewswire/ -- UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT IN RE TEVA SECURITIES LITIGATION No.

Bleichmar Fonti & Auld LLP Announce a Proposed Class Action Settlement Involving Purchasers of Teva Pharmaceutical Securities

AbbVie

Bristol-Myers

Charter Communications

Kroger

Mastercard

Marsh & McLennan

Royalty Pharma

Sirius XM Holdings Inc

Visa

Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too.

10 Stocks Warren Buffett Is Selling

Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.

TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates

Teva Pharmaceutical Industries Ltd. (TEVA) CEO Kåre Schultz on Q4 2021 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Ltd's  TEVA Q4 sales reached $4.1 billion, shrinking 8% Y/Y, missing the consensus of $4.29 billion.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are Teva Pharmaceutical Shares Trading Higher Today?

Teva Pharmaceutical Industries beat fourth-quarter profit expectations as gains in North American sales of Huntington's disease treatment Austedo and migraine product Ajovy offset declines in generics.

Teva Pharm Q4 profit rises, sees more growth in key drugs

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -2.01% shed 1.2% in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations but revenue that missed, as COVID-19 continued to impact patient behavior and prescribing patterns.

Teva stock falls after revenue falls below expectations, full-year profit outlook misses

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021. Q4 2021 and FY 2021 highlights:   Q4 2021 FY 2021   Revenues   $4.1 billion $15.9 billion GAAP diluted EPS   $(0.14) $0.38 Non-GAAP diluted EPS   $0.77 $2.58 Cash flow generated from operating activities   $456 million $798 million Free cash flow   $716 million $2,196 million 2022 business outlook: Revenues are expected to be $

Teva Reports Fourth Quarter and Full Year 2021 Financial Results

Teva Pharmaceutical Industries Ltd  TEVA has reached a settlement worth $225 million to resolve claims the Company fueled an opioid epidemic in Texas. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Teva, Texas Enter $225M Opioid Settlement Agreement

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state's and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan® (naloxone hydrochlor

Teva Reaches Agreement With Texas to Settle the State's Opioid-Related Claims

General Motors

Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.

Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?

We expect a positive resolution to TEVA's opioid lawsuit in New York state, similar to California and Oklahoma. Previously, a New York judge ruled TEVA guilty in the opioid lawsuit. Management has also been competent in debt refinancing and deleveraging, which resulted in a 32.6% reduction by $11.7B since 2016.

Teva: Competent Management Despite Lawsuits And Debts

Bank of America

Value should be the name of the game in 2022.

2 Best Warren Buffett Value Stocks to Buy Right Now

Amazon

Riding the Oracle of Omaha's coattails has long been a moneymaking strategy.

5 Buffett Stocks to Buy Hand Over Fist in 2022

Trulieve Cannabis Corp.

Zoom Video

These beaten-down growth and value stocks have all the tools necessary to reverse course.

3 Turnaround Stocks That Can Bounce Back Big Time in 2022

Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.

Teva settles shareholder lawsuit over generic drug pricing for $420 million

Hewlett Packard

Realty Income Corp

Qorvo

ViacomCBS

Vici Properties

These stocks to buy are above their lows and appear overvalued. They have more upside as growth drivers emerge lifting their prospects.

7 Stocks to Buy That Are Nowhere Near Being Overvalued

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2021 financial results, as well as on its financial guidance for 2022, on Wednesday, February 9, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers: United States 1-877-870-9135;

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022

Teva Pharmaceutical Industries Limited's (TEVA) CEO Kåre Schultz on 40th Annual JPMorgan Healthcare Conference- Conference Call Transcript

News for Teva Pharmaceutical Stock (TEVA)